Literature DB >> 29896035

Targeting Remission in Moderate-to-Severe Crohn's Disease.

Troy Kish.   

Abstract

Therapeutic options in development for the treatment of Crohn's disease represent a broad range of approaches to this complex disease. This active pipeline contains a combination of both small-molecule entities and targeted monoclonal antibodies.

Entities:  

Year:  2018        PMID： 29896035      PMCID： PMC5969213     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  9 in total

Review 1.  Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis.

Authors:  K M Das
Journal:  Dig Dis Sci       Date:  1999-01       Impact factor: 3.199

2.  Filgotinib for Crohn's disease-expanding treatment options.

Authors:  Ashwin N Ananthakrishnan
Journal:  Lancet       Date:  2016-12-15       Impact factor: 79.321

3.  Crohn's disease evaluation and treatment: clinical decision tool.

Authors:  William J Sandborn
Journal:  Gastroenterology       Date:  2014-07-18       Impact factor: 22.682

4.  Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.

Authors:  Séverine Vermeire; Stefan Schreiber; Robert Petryka; Tanja Kuehbacher; Xavier Hebuterne; Xavier Roblin; Maria Klopocka; Adrian Goldis; Maria Wisniewska-Jarosinska; Andrey Baranovsky; Robert Sike; Kremena Stoyanova; Chantal Tasset; Annegret Van der Aa; Pille Harrison
Journal:  Lancet       Date:  2016-12-15       Impact factor: 79.321

5.  Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.

Authors:  Brian G Feagan; William J Sandborn; Geert D'Haens; Julián Panés; Arthur Kaser; Marc Ferrante; Edouard Louis; Denis Franchimont; Olivier Dewit; Ursula Seidler; Kyung-Jo Kim; Markus F Neurath; Stefan Schreiber; Paul Scholl; Chandrasena Pamulapati; Bojan Lalovic; Sudha Visvanathan; Steven J Padula; Ivona Herichova; Adina Soaita; David B Hall; Wulf O Böcher
Journal:  Lancet       Date:  2017-04-12       Impact factor: 79.321

6.  Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial.

Authors:  Séverine Vermeire; Sharon O'Byrne; Mary Keir; Marna Williams; Timothy T Lu; John C Mansfield; Christopher A Lamb; Brian G Feagan; Julian Panes; Azucena Salas; Daniel C Baumgart; Stefan Schreiber; Iris Dotan; William J Sandborn; Gaik W Tew; Diana Luca; Meina T Tang; Lauri Diehl; Jeffrey Eastham-Anderson; Gert De Hertogh; Clementine Perrier; Jackson G Egen; John A Kirby; Gert van Assche; Paul Rutgeerts
Journal:  Lancet       Date:  2014-05-09       Impact factor: 79.321

7.  ACG Clinical Guideline: Management of Crohn's Disease in Adults.

Authors:  Gary R Lichtenstein; Edward V Loftus; Kim L Isaacs; Miguel D Regueiro; Lauren B Gerson; Bruce E Sands
Journal:  Am J Gastroenterol       Date:  2018-03-27       Impact factor: 10.864

8.  Factors affecting outcomes in Crohn's disease over 15 years.

Authors:  Jacques Cosnes; Anne Bourrier; Isabelle Nion-Larmurier; Harry Sokol; Laurent Beaugerie; Philippe Seksik
Journal:  Gut       Date:  2012-03-02       Impact factor: 23.059

9.  Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn's disease: report of the OPERA study.

Authors:  William J Sandborn; Scott D Lee; Dino Tarabar; Edouard Louis; Maria Klopocka; Jochen Klaus; Walter Reinisch; Xavier Hébuterne; Dong-Il Park; Stefan Schreiber; Satyaprakash Nayak; Alaa Ahmad; Anindita Banerjee; Lisa S Brown; Fabio Cataldi; Kenneth J Gorelick; John B Cheng; Mina Hassan-Zahraee; Robert Clare; Geert R D'Haens
Journal:  Gut       Date:  2017-10-05       Impact factor: 23.059
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.